LBA18 - A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer
| Autor: | Beeram, M., Tolaney, S.M., Beck, J.T., Dickler, M.N., Conlin, A.K., Dees, C., Helsten, T.L., Conkling, P.R., Edenfield, W.J., Richards, D.A., Kambhampati, S.R.P., Costigan, T.M., Chan, E., Pant, S., Kalinsky, K., Burris, H.A., Becerra, C.H., Rexer, B.N., Puhalla, S.L., Goetz, M.P. |
|---|---|
| Zdroj: | In Annals of Oncology 1 October 2016 27 Supplement 6:vi556-vi556 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|